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S162 Oral PresentationsSSI use was 152 (13-981) days. At 6months and 1 year, 63% and 83%
of patients were off all immunosuppressive therapy, respectively.
With a median follow-up of 26 months, cumulative incidence of
chronic GVHD was 10%. Only 3 patients have died with refractory
GVHD. These results extend our previous observations that post-
transplantation Cy is effective single agent strategy for prophylaxis
of acute GVHD with both a low rate of grade III-IV and more
than half of the patients never requiring additional SSI. The limited
use of SSI may be responsible for low infectious rate and excellent
immune reconstitution seen in these patients. This approach also
provides novel platform to facilitate the use of post-transplant immu-
notherapy aimed at reducing relapse.20
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Objective: To evaluate the impact of HLA matching and differ-
ence in matching degree among transplants from unrelated donors
(UD) on different outcomes in chronic lymphocytic leukemia
(CLL).
Materials & Methods: We have analyzed 370 CLL patients who
underwent an allogeneic HSCT reported to the EBMT registry.
There were 280 males (75%) and 90 females with a median age of
53 years (24-69). At transplant, 294 among 317 evaluated patients
had a good performance status (PS) (93%), 43 patients were in CR
(12%), 160 in PR (46%), 44 in SD (13%) and 103 in PD (29%)
among 349 evaluated patients. Two hundred and sixty six patients re-
ceived a reduced intensity conditioning regimen (RIC) and 103
a standard (Std) conditioning; 313 patients received PBSC, 56 BM
and 2 cord blood cells from 198HLA siblings, and 172 unrelated do-
nors (UD).According to the registry, there were 198 HLA siblings,
135matchedUD (MUD) and 37mismatchedUD (MMUD).We fo-
cused on UD and re-analyzed all HLA typings for patients and do-
nors, after classification we found: 31 well matched (10/10, 8/8) in
high resolution), 30 matched in low resolution and 111 mismatched
in high resolution.
We found a high significant difference in term of OS between the
siblings, well & partially matched groups versus low & MMUD
groups (p5 0.002) (figure2). [OS at 3 & 5 years: Siblings: 68.3%
(61.8-75.5) and 57.2% (49.8-65.6); well matched: 60.8% (43.1-85.8)
from 3 to 5 years, low resolution &MMUD: 50.5% (43.1-60.1) and
39.6% (29.5-50.2) respectively]. We observed also a high significant
difference in term of transplant relatedmortality (TRM) between the
same groups (p5 0.0024) (figure4). The multivariate analysis using
Cox model studying age, pre-transplant status, gender, PS, cells
source, ABO compatibility, conditioning and different HLA groups,
showed a significant impact of 3 factors onOS: age [HR5 1.04 (1.02-
1.6) p5 0.001], PS [HR5 2.75 (1.5-5.1) p5 0.001] and HLA
MMUD+Low resolution group [HR5 1.43 (1.01-2.01) p5 0.04].
The same factors were also highly significant in multivariate analysis
in term of TRM (age: HR5 1.04 (1.001-1.07) p5 0.0033; PS:
HR5 2.47 (1.1-5.4) p5 0.009 and HLA MMUD group: HR5 1.8
(1.07-3.37) p5 0.004.21
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This retrospective report assessed the outcome of 629 patients
aged$60 years and who received RIC allo-SCT, with a special em-
phasis on the comparison of the outcome of patients aged 60-65 and
patients aged .65 y.
The median age for the whole cohort was 62 (range, 60-71) y. 378
patients (55%) had a myeloid malignancy, while 240 (38%) had lym-
phoid malignancies, and 11 (2%) had other diseases. 386 patients
(61%) received allo-SCT from an HLA-matched related donor,
while 199 patients (32%) received the graft from a MUD, and 44
(7%) frommismatched donors. The conditioning regimen consisted
of Fludarabine and Busulfan in 280 cases (44.5%), Fludarabine and
low dose TBI in 150 cases (24%). The remaining 199 patients
(32%) received other so-called RIC regimens.
With a median follow-up of 9 (range, 1-90) m., grade II-IV and
grade III-IV acute GVHD occurred in 29% (n5 182) and 12%
(n5 76) of patients, respectively. Chronic GVHD was observed
in 145 patients (23%; limited: n5 67; extensive: n5 72; unknown
stage: n5 6). 180 patients died of transplant-related causes
(TRM: 29%). The estimates of overall survival (OS) at 1 and 2
years were 57% (95%CI, 53-62%) and 47% (95%CI, 42-52%),
respectively.
In order to assess the applicability of RIC allo-SCT to the older
age group, we compared the outcome of patients aged from 60 to
65 y. (n5 516) and those aged .65 y. (n5 113). Except for age, in
univariate analysis, these 2 groups were not statistically different in
terms of demographic, disease or transplant characteristics. The
incidences of grade II-IV and grade III-IV acute GVHD were com-
parable between both groups (29% vs. 30%, p5NS; and 12% vs.
12%; p5NS). The TRM incidence was 29% in the younger group
vs. 27% in the older group (p5NS). The estimates of OS at one and
2 years were 58% (95%CI, 53-62%) and 47% (95%CI, 42-52%) in
the younger age group and 55% (95%CI, 44-65%) and 48%
(95%CI, 37-60%) in the older age group (p5NS). In a Cox multi-
variate analysis accounting for all relevant factors, age.65 y. was not
found to be a statistically significant factor associated with worsened
survival.
In all, this data support the use of RIC-allo-SCT in patients.60 y.
Outcome of patients aged.65 y. appears to be comparable to that of
patients aged 60-65 y. Physiologic aging is likely more important
than chronologic aging. With the refinement of comorbidities scor-
ing systems, age per se (at least up to 70 y.) should not be a contrain-
dication to perform RIC allo-SCT.22
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While non-myeloablative conditioning significantly reduces mor-
bidity and mortality after allogeneic hematopoietic cell transplanta-
tion (HCT), the risk of allograft rejection is increased. Persistent
host cells mediate host-vs-graft alloreactivity or occupy niches in
the hematopoietic microenvironment. Here we studied engraftment
and hematopoietic reconstitution in BALB.K mice given non-mye-
loablative radiation and purified hematopoietic stem cells (HSC:
cKIT +Thy1.1loSca1 + Lin-) +/- T cells (TC) from AKR/J donors,
a MHC-identical (H-2 K) model with high barriers to engraftment.
Recipients of pure HSC regularly achieved stable mixed chimerism.
However, if grafts contained CD4 TC (but not CD8 TC) donor
lymphopoiesis was completely abolished in 80% of hosts, even
long-term. This suppression was associated with bone marrow
(BM) lymphopenia (\5% vs .40% after HSC alone), and hypocel-
lularity (median 3.8 vs 13.3 x10^6 cells/2 legs; p5 0.0003) at 2 weeks
post-HCT. B cell reconstitution was the most severely affected (6%
vs 75% of lymphocytes). At this early time point there was expansion
of donor and host CD4 TC, each comprising 6% of BM cells (vs
